Study #2024-1706
A multicentre, open-label, non-randomized, phase 1b trial of NG-350A, a tumour-selective anti-CD40-expressing adenoviral vector, in combination with chemoradiotherapy in locally advanced rectal cancer (FORTRESS)
MD Anderson Study Status
Enrolling
Treatment Agent
NG-350A IV administration, Capecitabine oral administration
Description
The FORTRESS trial (NG-350A-03) is an open-label, single-arm, and multicentre trial of NG-350A in combination with chemoradiotherapy (CRT) in adult patients with locally advanced rectal cancer (LARC) and at least one risk factor for local or distant recurrence.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Locally Advanced Rectal Cancer (LARC)
Study phase:
Phase I
Physician name:
Sonal Noticewala
Department:
Radiation Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.